Clinical trials · Illinois
Infectious Disease clinical trials in Illinois
We’re tracking 29 recruiting infectious disease studies with a site in Illinois — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT05013944Recruiting
Join a patient registry to support future research
This trial is a “patient registry,” which collects health information over time to help researchers plan and run future studies. It may help by contributing your experience so new treatments can be tested more effectively.
Arlington Heights, IllinoisAges 18 years+ - NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Chicago, IllinoisAges 16–45 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Chicago, IllinoisAges 50 years+ - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Chicago, IllinoisAges 18–75 - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
Chicago, IllinoisAges 18–55 - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Chicago, IllinoisAges 18 years+ - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Chicago, IllinoisAges Up to 2 days - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Chicago, IllinoisAges 18 years+ - NCT06071767RecruitingPhase 1/Phase 2
Immune therapy trial for early-treated HIV
This study tests whether a combination of three immune therapies can help control HIV without daily medication. You may qualify if you started HIV treatment very early and have had a suppressed viral load for at least a year.
Chicago, IllinoisAges 18 years+ - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Chicago, IllinoisAges 18 years+ - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Chicago, IllinoisAges 13–20 - NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Chicago, IllinoisAges 18–70 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Chicago, IllinoisAges Up to 3 days - NCT04364503Enrolling by invitation
Study that analyzes de-identified patient samples and records
This trial checks how well patient samples and health records can be analyzed when names are removed (“de-identified”) and privacy rules are followed. You might be included if you agree in writing and your sample data can be used for this research and/or your doctor requests it.
Itasca, IllinoisAges Any age - NCT07069400Recruiting
Observational study of adults with acute infection
This study observes adults hospitalized with a new or recent infection (symptoms started within 30 days). The goal is to learn more about how infections affect people in the hospital, without testing any new drugs or treatments.
Chicago, IllinoisAges 18 years+ - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Evanston, IllinoisAges 18–55 - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
Chicago, IllinoisAges 18 years+ - NCT05272241Recruiting
Asthma registry that helps researchers learn about asthma
This study enrolls people in specific cities to collect health information that helps researchers better understand asthma and how to recruit future studies. It may help by improving knowledge about asthma types and care in real-world settings.
Chicago, IllinoisAges Any age - NCT05947071RecruitingPhase 2
Higher-dose flu vaccine versus standard dose in child transplant patients
This trial compares a higher-dose flu vaccine to the standard dose in children who recently received a kidney, heart, and/or liver transplant. It aims to see which dose better protects children against influenza while checking for safety.
Chicago, IllinoisAges 3–17 - NCT06004739Recruiting
Antibiotics for older adults with delirium and abnormal urine tests
This trial tests whether giving antibiotics helps older adults in the hospital who have delirium (sudden confusion) and signs of bacteria in their urine but no clear urinary infection. It aims to see if treatment can improve confusion and avoid unnecessary antibiotics.
Chicago, IllinoisAges 60 years+ - NCT06034080Recruiting
Cutting down unneeded antibiotics for children's ear infections
This study tests ways to help doctors avoid prescribing antibiotics when they are not needed for children with ear infections. If you are a parent of a child diagnosed with an ear infection or a healthcare provider, you may be able to join different parts of the study.
Chicago, IllinoisAges 6 months–17 years - NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Chicago, IllinoisAges 18 years+ - NCT06919003RecruitingPhase 2
Improving kidney transplant with a single injection of a protective protein
This trial tests whether a single injection of C1 esterase inhibitor into a donated kidney during preservation can improve transplant outcomes. It is for adults on dialysis waiting for a deceased-donor kidney who meet specific blood and tissue matching requirements.
Chicago, IllinoisAges 18–75 - NCT06504160RecruitingPhase 1
Testing a bacteria cream for eczema (TIME-2)
This study tests whether a cream made from a friendly skin bacteria (Staphylococcus hominis) can help treat eczema. Eligible participants will apply the cream to eczema patches on their arms, legs, or trunk for several weeks.
Chicago, IllinoisAges 6 years+
Infectious Disease trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting infectious disease studies listed above.
- Northwestern University · 10 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 5 studies
- Northwestern Memorial Hospital · 2 studies
- University of Chicago · 2 studies
- Alliance for Clinical Trials in Oncology
- Anova Enterprises, Inc.
- Labcorp - Litholink
- Rush University Cook County Hospital Clinical Research Site
What taking part in a infectious disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there infectious disease clinical trials in Illinois?
- Yes. We're currently tracking 29 recruiting infectious disease studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a infectious disease study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a infectious disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New infectious disease studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.